RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma.

By M. Nikiforova, R. Lynch, P. Biddinger, E. Alexander, Gerald W. Dorn II, G. Tallini, T. Kroll, Y. Nikiforov. Journal of Clinical Endocrinology and Metabolism, 2003

718 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Immunology, Reproductive Medicine

View Paper: https://www.semanticscholar.org/paper/1723bcec54c7d8c5ab58929ed66dce84f2f47979

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

1. Y. Nikiforov
2. M. Nikiforova

Citations in the corpus

• High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. (2003, methodology): “format followed by fluorescence melting curve analysis (18, 19).”
• MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility. (2008, methodology): “PPAR rearrangements were detected from RNA by RT-PCR as previously reported (20, 25).”
• Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. (2009, background): “licular carcinomas, the second most common type of thyroid cancer, harbor either RAS or PAX8/PPAR mutations, which are identified in approximately 80% of these tumors (22).”